19.84

3.98% 0.76

Syndax Pharmaceuticals Inc (SNDX)

Overview News Price History Option Chain Financials Discussions Forecast

Syndax Pharmaceuticals Inc stock is traded at $19.84, with a volume of 1.25M. It is up +3.98% in the last 24 hours and down -17.78% over the past month. Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Previous Close:

$19.08

Open:

$19.08

24h Volume:

1.25M

Relative Volume:

0.70

Market Cap:

$1.77B

Revenue:

$217.42M

Net Income/Loss:

$-243.25M

P/E Ratio:

-7.0979

EPS:

-2.7952

Net Cash Flow:

$-278.35M

1W Performance:

-2.75%

1M Performance:

-17.78%

6M Performance:

-3.13%

1Y Performance:

+34.69%

1-Day Range:

$18.82

$19.86

1-Week Range:

$18.82

$20.71

52-Week Range:

$12.99

$25.59

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name

Syndax Pharmaceuticals Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

781-419-1400

Address

730 THIRD AVENUE, NEW YORK, MA

Employee

298

Twitter

@syndax

Next Earnings Date

2026-08-03

Latest SEC Filings

SNDX's Discussions on Twitter

Compare SNDX vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SNDX Syndax Pharmaceuticals Inc	19.84	1.77B	217.42M	-243.25M	-278.35M	-2.7952
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-16-25	Resumed	H.C. Wainwright	Buy
Sep-10-25	Resumed	Stifel	Buy
Sep-04-25	Resumed	Guggenheim	Buy
Aug-05-25	Reiterated	BTIG Research	Buy
Jul-10-25	Initiated	Goldman	Buy
Oct-24-24	Initiated	UBS	Buy
Jun-28-24	Initiated	Jefferies	Buy
Jan-31-24	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Dec-22-23	Initiated	Mizuho	Buy
Oct-25-23	Initiated	BofA Securities	Buy
Oct-11-23	Initiated	Goldman	Buy
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jul-11-23	Initiated	Guggenheim	Buy
Apr-17-23	Resumed	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jan-03-23	Initiated	JP Morgan	Overweight
Jul-28-22	Resumed	B. Riley Securities	Buy
Apr-11-22	Initiated	H.C. Wainwright	Buy
Feb-15-22	Initiated	Goldman	Buy
Jun-04-21	Resumed	Robert W. Baird	Outperform
May-25-21	Initiated	Citigroup	Buy
Feb-18-21	Initiated	B. Riley Securities	Buy
Dec-03-20	Initiated	Stifel	Buy
May-22-20	Upgrade	Citigroup	Neutral → Buy
May-22-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-18-20	Downgrade	Citigroup	Buy → Neutral
May-11-20	Reiterated	H.C. Wainwright	Buy
Mar-04-20	Initiated	Barclays	Overweight
Jan-13-20	Reiterated	H.C. Wainwright	Buy
Mar-08-19	Reiterated	H.C. Wainwright	Buy
Jan-04-19	Initiated	Robert W. Baird	Outperform
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy
Mar-16-17	Initiated	FBR & Co.	Outperform
Mar-02-17	Initiated	Instinet	Buy
Oct-07-16	Initiated	Guggenheim	Buy
Mar-28-16	Initiated	Citigroup	Buy
Mar-28-16	Initiated	JMP Securities	Mkt Outperform
Mar-28-16	Initiated	Morgan Stanley	Overweight

View All

Syndax Pharmaceuticals Inc Stock (SNDX) Latest News

Aug 12, 2026

The Technical Signals Behind (SNDX) That Institutions Follow - Stock Traders Daily

Aug 12, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $40.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Aug 11, 2026

Syndax Pharmaceuticals (SNDX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat

Aug 11, 2026

Aug 09, 2026

Hennion & Walsh Asset Management Inc. Increases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Aug 09, 2026

Aug 08, 2026

Bank of America Corp DE Decreases Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Aug 08, 2026

Aug 07, 2026

Net margin % of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView

Aug 07, 2026

Long term debt to total assets ratio of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView

Aug 07, 2026

Price to sales forward of Syndax Pharmaceuticals Inc – HAM:1T3 - TradingView

Aug 07, 2026

State Street Corporation (SNDX) discloses 5.66M-share, 6.4% holding in Syndax - Stock Titan

Aug 07, 2026

How Surging Revuforj and Niktimvo Sales and Narrowing Losses Could Shape Syndax Pharmaceuticals (SNDX) Investors - Yahoo Finance

Aug 07, 2026

Syndax Pharmaceuticals Inc (1T3) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks

Aug 07, 2026

Earnings Update: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Just Reported And Analysts Are Trimming Their Forecasts - simplywall.st

Aug 07, 2026

HC Wainwright Brokers Decrease Earnings Estimates for SNDX - MarketBeat

Aug 07, 2026

Aug 06, 2026

Syndax Pharmaceuticals Inc (1T3) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks

Aug 06, 2026

Surging Revenue And Narrower Losses Might Change The Case For Investing In Syndax Pharmaceuticals (SNDX) - webull.com

Aug 06, 2026

What is HC Wainwright's Estimate for SNDX FY2029 Earnings? - MarketBeat

Aug 06, 2026

Syndax Pharmaceuticals (SNDX) Stock Climbs On Revenue Strength As Losses Persist - Sahm

Aug 06, 2026

BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Cuts Target Price to $26 - Moomoo

Aug 06, 2026

Aug 05, 2026

A Quick Look at Today's Ratings for Syndax Pharmaceuticals(SNDX.US), With a Forecast Between $26 to $57 - Moomoo

Aug 05, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Aug 05, 2026

Five New Syndax Employees Receive Stock Options With 4-Year Vesting - Stock Titan

Aug 05, 2026

Syndax Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-08-05 - Seeking Alpha

Aug 05, 2026

Syndax Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $38.27, Implies 101% Upside - TradingView

Aug 05, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down on Disappointing Earnings - MarketBeat

Aug 05, 2026

SNDX Maintains Rating by HC Wainwright & Co. -- Price Target Low - GuruFocus

Aug 05, 2026

HC Wainwright Has Lowered Expectations for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price - MarketBeat

Aug 05, 2026

Sei Investments Co. Grows Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Aug 05, 2026